Results 61 to 70 of about 174,143 (324)

Maximal irredundant families of minimal size in the alternating group

open access: yes, 2019
Let $G$ be a finite group. A family $\mathcal{M}$ of maximal subgroups of $G$ is called `irredundant' if its intersection is not equal to the intersection of any proper subfamily.
Garonzi, Martino, Lucchini, Andrea
core   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

open access: yesMolecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern   +7 more
wiley   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

Embeddings and chains of free groups [PDF]

open access: yes, 2008
We build two non-abelian CSA-groups in which maximal abelian subgroups are conjugate and ...
Jaligot, Eric, Neman, Azadeh
core   +3 more sources

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad   +17 more
wiley   +1 more source

Generators of Maximal Subgroups of Harada-Norton and some Linear Groups

open access: yesOpen Chemistry, 2019
Group theory, the ultimate theory for symmetry, is a powerful tool that has a direct impact on research in robotics, computer vision, computer graphics and medical image analysis.
Liu Jia-Bao   +3 more
doaj   +1 more source

On subfields of the Hermitian function fields involving the involution automorphism

open access: yes, 2017
A function field over a finite field is called maximal if it achieves the Hasse-Weil bound. Finding possible genera that maximal function fields achieve has both theoretical interest and practical applications to coding theory and other topics.
Ma, Liming, Xing, Chaoping
core   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

open access: yesMolecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard   +12 more
wiley   +1 more source

Constructing maximal subgroups of orthogonal groups [PDF]

open access: yesLMS Journal of Computation and Mathematics, 2010
AbstractIn this paper we construct the maximal subgroups of geometric type of the orthogonal groups in dimension d over GF(q) in O(d3+d2log q+log qlog log q) finite field operations.
Holt, Derek F., Roney-Dougal, Colva M.
openaire   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy